J. B. Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 291.80B |
| Revenue (ttm) | 35.92B |
| Net Income (ttm) | 5.87B |
| Shares Out | n/a |
| EPS (ttm) | 36.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Aug 14, 2024 |
| Volume | 147,735 |
| Open | 1,850.55 |
| Previous Close | 1,854.05 |
| Day's Range | 1,850.55 - 1,910.00 |
| 52-Week Range | 1,371.00 - 2,030.00 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About JBCHEPHARM
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-cen... [Read more]
Financial Performance
In 2023, JBCHEPHARM's revenue was 34.84 billion, an increase of 10.63% compared to the previous year's 31.49 billion. Earnings were 5.53 billion, an increase of 34.84%.
Financial StatementsNews
Stocks to Buy This Diwali: Kotak Securities sees JB Chemicals & Pharma reaching ₹2,255, with a 19.2% upside
Kotak Securities has added JB Chemicals & Pharma to its Diwali 2024 stock picks, assigning it a “Buy” rating with a target price of ₹2,255. Currently trading at ₹1,891, JB Chemicals offers an upside p...
Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83%
As of 2:38 PM, the Nifty Pharma index saw a mixed performance with some stocks showing notable gains while others faced losses. Natco Pharma, Glenmark, and Ajanta Pharma were the top gainers, while Gr...
Pharma Stocks Update: Granules up 3.56%, Ajanta Pharma gains 2.24% while JB Chemicals drops 2.82%, Mankind Pharma down 1.40% in mixed pharma stock performance
Pharma stocks have shown mixed performance in today’s trading session, with some major players gaining ground while others face declines. As of now, here’s how key pharmaceutical stocks are performing...
JB Chemicals faces valuation dispute over KKR’s 54% equity stake, potential M&A deal withdrawal looms; stock falls 4.28%
The largest M&A deal in India’s pharmaceutical industry for 2024 is reportedly facing significant hurdles. According to ET Now, JB Chemicals is in a disagreement over the valuation of KKR’s 54% equity...